Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients

Autor(es)

Garcia-Rosa, Sheila ^[1] ; Carvalho, Benilton S. ^[2] ; Guest, Paul C. ^{[1, 3]} ; Steiner, Johann ^{[4, 5]} ; Martins-de-Souza, Daniel ^{[6, 1, 7, 8, 3]}

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Rua Monteiro Lobato 255, BR-13083862 Campinas, SP - Brazil

^[2] Univ Campinas UNICAMP, Inst Math Stat & Sci Computat, Dept Stat, Campinas, SP - Brazil

^[3] Martins-de-Souza, Daniel, DOr Inst Res \& Educ IDOR, Sao Paulo, Brazil.Garcia-Rosa, Sheila, Univ Campinas UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Rua Monteiro Lobato 255, BR-13083862 Campinas, SP - Brazil

^[4] Ctr Behav Brain Sci, Magdeburg - Germany

^[5] Univ Magdeburg, Dept Psychiat & Psychotherapy, Magdeburg - Germany

^[6] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil

^[7] DOr Inst Res & Educ IDOR, Sao Paulo - Brazil

^[8] Univ Estadual Campinas, Expt Med Res Cluster EMRC, BR-13083862 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF PROTEOMICS; v. 224, JUL 30 2020.
• Citações Web of Science: 0

Resumo

Antipsychotics are the main line of treatment for schizophrenia. Even though there are significant rates of medication drop out due to side effects and limited response of approximately 50% of patients. This is likely due to incomplete knowledge in how these drugs act at the molecular level. To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment. Blood plasma samples were processed and analyzed by label-free quantitative shotgun proteomics using two-dimensional nano-liquid chromatography, coupled online to a Synapt G2-Si mass spectrometer. Data were obtained in MSE mode (data-independent acquisition) in combination with ion-mobility (HDMSE). We were able to identify a potential panel of proteins that might predict a positive outcome to olanzapine and risperidone treatment. The proteins found to be differentially abundant between T0 and T6 in good responders compared to poor responders were analyzed in silico for enrichment pathways and found to be mostly involved with immune system functions. This data can contribute to better understand the biochemical signaling mechanisms peripherally triggered by antipsychotic medication and eventually used to develop surrogate biomarker tests to help improve treatment outcomes and guide development of new treatment approaches. Significance: The application of proteomics to the study of the atypical antipsychotic effects on the blood plasma proteome from schizophrenia patients could help in the search for new targets to improve the current therapies, as well as in the development of new therapeutic strategies. In this original article, we provided clues that atypical antipsychotics might be associated with good response by modulating proteins that play a role in inflammation and/or immune system pathways. In addition, the proteins with differential abundance found in the comparison between good and poor responders at the baseline might compose a signature for prediction of response effectiveness. (AU)

• Processo FAPESP: 17/25588-1 - Da compreensão básica a biomarcadores clínicos para a esquizofrenia: um estudo multidisciplinar centrado na neuroproteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 14/10068-4 - EMU concedido no processo 13/08711-3: espectrômetro de massas Waters SYNAPT G2-Si HDMs + nanoACQUITY UPLC
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 16/18715-4 - Estabelecimento do papel de hnRNPs envolvidas em esquizofrenia através do mapeamento de suas redes de interação
• Beneficiário: Mariana Fioramonte
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado